Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Sv Life Sciences Fund Vi, L.P. investment portfolio
Sv Life Sciences Fund Vi, L.P. has made numerous investments in companies such as Enara Bio, Artios Pharma, and Sitryx Therapeutics within the Healthcare & Life Sciences sector.
vc
Portfolio
3
Team
0
Portfolio (3)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Artios Pharma Limited Artios Pharma Limited develops DNA‑damage‑response‑based cancer therapeutics. Its pipeline includes the ATR inhibitor alnodesertib and the Polθ inhibitor ART6043, targeting hard‑to‑treat solid tumours. | Healthcare & Life Sciences | Cambridge | Confirmed | 2025-12-28 |
| Enara Bio Limited Enara Bio is a biotechnology company that discovers novel “Dark Antigen” cancer targets and develops bispecific T‑cell engager immunotherapies for solid tumours. It collaborates with pharmaceutical partners such as Boehringer Ingelheim to advance these therapies toward clinical trials. | Healthcare & Life Sciences | Oxford | Confirmed | 2025-11-07 |
Shareholding changes (4)
Sv Life Sciences Fund Vi, L.P.'s positions across portfolio companies2025
- SERIES D SHARES 0 → 3,420,796
- SERIES D1 SHARES 0 → 702,283
- SERIES A PREFERRED 5,858,097 → 8,279,061
- SERIES A-1 PREFERRED 1,348,577 → 1,905,901
- SERIES B-1 PREFERRED 4,364,549 → 7,092,392